Progressive Ventricles Enlargement and Cerebrospinal Fluid Volume Increases as a Marker of Neurodegeneration in Patients with Spinal Cord Injury: A Longitudinal Magnetic Resonance Imaging Study by Seif, M et al.
Progressive Ventricles Enlargement and Cerebrospinal
Fluid Volume Increases as a Marker
of Neurodegeneration in Patients with Spinal Cord Injury:
A Longitudinal Magnetic Resonance Imaging Study
Maryam Seif,1,2 Gabriel Ziegler,3,4 and Patrick Freund1,2,5
Abstract
Next to gray and white matter atrophy, cerebrospinal fluid (CSF) volume and ventricular dilation may be surrogate bio-
markers for brain atrophy in spinal cord injury (SCI). We therefore aimed to track brain atrophy by means of CSF volume
changes and ventricular enlargements over two years after SCI. Fifteen patients with SCI and 18 healthy controls underwent
a series of T1-weighted scans during five time points over two years. Changes of CSF/intracranial volume (CSF/ICV) ratio,
CSF volume, and ventricular enlargement rate over time were determined. Sample sizes with 80% power and 5% signifi-
cance were calculated to detect a range of treatment effects for a two-armed trial. There was a significant cross-sectional
increased CSF/ICV ratio in patients compared with controls at each time point ( p< 0.02). The rate of CSF/ICV changes,
however, was not significantly different between groups over time. CSF volume increased linearly over bilateral sensori-
motor cortices (left: p= 0.002, right: p= 0.042) and in the supracerebellar space ( p< 0.001) within two years. An acceleration
of the enlargement within the third ( p= 0.017) and the fourth ( p= 0.006) ventricles was observed in patients over time.
Sample size estimation for six-month trials with CSF volume requires 25 patients per treatment arm to detect a hypothetical
treatment effect in terms of slowing of atrophy rate of 30%. This study shows that SCI-induced changes in CSF/ICV ratio
and ventricular expansion rate provide additional information on the neurodegenerative processes after injury. The sensitivity
to scoring treatment effects speaks to its potential to serve as a sensitive biomarker in addition to local atrophy measures.
Keywords: brain volume; CSF volume; spinal cord injury; VBM; ventricle enlargement
Introduction
Traumatic spinal cord injury (SCI) leads in most patients toprofound neurological dysfunction and paralysis below the
level of lesion1 as information flow between supraspinal and spinal
neuronal networks is impaired.2 Functional recovery after human
SCI is restricted but can be fostered by intensive neuroreha-
bilitation. The neuronal mechanisms underlying neurological and
functional recovery, however, are still not well understood because
of the complex relationship between neurodegeneration and plas-
ticity. The ability to track trauma-induced structural changes across
the neuraxis provides the opportunity to quantify neurodegenera-
tion in vivo3 and recovery-related plasticity,4 which may identify
new treatment targets.
After SCI, serial magnetic resonance imaging (MRI) studies
revealed progressive neurodegeneration, both in the gray matter
(GM) and white matter (WM), along the entire trajectory of the
motor5 and sensory systems6 above the level of injury. Recently, a
follow-up study in the same patient cohort revealed that these
changes continued for at least two years post-SCI.7 Crucially, the
magnitude of neurodegeneration at the level of the spinal cord,
brainstem, and cortex over the first six months predicted clinical
outcome at two years, independent of early clinical changes.7
Nevertheless, potential neuroimaging biomarkers for global
brain atrophy such as intracranial volume (ICV), cerebrospinal
fluid (CSF) volume changes, and ventricular enlargement were not
investigated. ICV, CSF volume, and ventricle enlargement mea-
surements are reliable morphometric features to determine atrophy
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patterns in patients with mild cognitive impairment, Alzheimer
disease,8 Parkinson disease,9 Huntington disease,10 and traumatic
brain injury (TBI).11 For instance, early ventricular dilatation was
observed in the course of significant cognitive decline in patients
with Parkinson disease.9 In addition, it has been shown that the
CSF/ICV ratio, besides its potential to quantitate general brain at-
rophy,12 does not depend on sex and therefore may be used in
mixed sex studies as well.13
The rationale for the use of these markers of global brain atrophy
measures in SCI arises as the trauma to the spinal cord triggers a
cascade of inflammatory processes that spreads across the central
nervous system (CNS).14–17 Chronic inflammation is associated
with neurodegeneration and hence could lead to volumetric fluc-
tuations in brain tissue.18,19 Interestingly, measures of global brain
atrophy as well as longitudinal MRI findings are now used as sur-
rogate end-points in clinical trials9,10,19 next to measures of focal
GM and WM neurodegeneration to complement clinical assess-
ments for disease-modifying trials. It remains to be established,
however, whether MRI-derived measurement of global brain at-
rophy and ventricle expansions (both are reflected by increases in
CSF volume) are sensitive and accurate in identifying disease-
related changes in patients with SCI.
The aim of this study was to investigate the trajectory of pro-
gressive global brain atrophy (i.e., CSF/ICV ratios, volumetric CSF
changes) and local brain atrophy (i.e., ventricular enlargement)
over two years in the same SCI patient cohort that previously
showed enduring neurodegenerative changes in the cortical GM
andWM after SCI.7 To track brain atrophy, we applied longitudinal
Voxel Based Morphometry (VBM)20,21 on serially acquired high
resolution T1-weighted MR images. We estimated the sample sizes
for a six-month trial of CSF volume that might inform the design of




The longitudinal study was approved by the local ethics com-
mittee of Zurich (EK-2010-0271), and written informed consent
was obtained from each subject before the examination. Fifteen
patients with SCI (nine tetraplegic and six paraplegic patients,
mean age, 48 years –19; age range, 19–75 years, Table 1) and 18
healthy controls (mean age, 35 years –10, age range, 23–65 years)
underwent a series of T1-weighted three-dimensional Magnetiza-
tion Prepared Rapid Acquisition Gradient Echo, (3D-MPRAGE)
scans during five time points over two years. The inclusion criteria
were traumatic subacute SCI patients with no head and brain le-
sions, no mental or medical disorders affecting functional results.
Patients underwent a comprehensive clinical assessment, including
the International Standards for the Neurological Classification of
Spinal Cord Injury protocol22 at baseline and at two months, six
months, 12 months, and 24 months follow-up.
MRI measurements
The 3D-MPRAGE sequence comprises the following pa-
rameters: field of view = 224 · 256mm2, matrix size = 224· 256,
repetition time = 2420msec, echo time= 4.18msec, readout band-
width = 150Hz per pixel, 1mm3 of resolution, flip angle a = 9 de-
grees, inversion time= 960msec, and total acquisition time of
9min. The first scan (baseline) was acquired at 49.67 (– 22) days
post-injury, the second scan at two, the third scan at six, the fourth
scan at 12, and the fifth scan at 24 months after injury. The images
on the first four time points were acquired using a 3T Magnetom
Verio (Siemens Healthcare, Erlangen, Germany), and for mea-
surements on the fifth time point, the scanner was upgraded to a 3T
Magnetom Skyrafit. We used a 16-channel radiofrequency receive
head and neck coil in combination with a spine matrix coil.
Trained radiographers positioned all participants in the same
supine position for each scan. Image acquisition over five time
points was completed successfully in 14 patients and in 18 healthy
controls. One patient died of causes unrelated to SCI after the
second time point. A total of 156 MRI datasets were analyzed from
33 participants. All T1-weighted 3D-MPARGE images acquired
from subjects were included in the VBM analysis.20,21
Brain volume
Global tissue volumes for GM, WM, and CSF at each time point
were calculated using the segmented T1-weighted images with
applying unified segmentation,23 and the total ICV was expressed
as the sum of volumes of all tissue classes. A previously established
global measure of CSF volume is the CSF volume-to-ICV (CSF/
ICV) ratio, calculated as the CSF volume divided by total brain
volume (sum of GM, WM, and CSF) to adjust for intersubject
differences in brain size.24 CSF/ICV ratio is used as a global at-
rophy marker associated with CSF volume.
To assess local change of CSF volume over time, longitudinal
VBM was applied within SPM12 (Wellcome Trust Centre for
Neuroimaging). Diffeomorphic registration was applied for longi-
tudinal MRI, and resulting midpoint images were segmented,20
Non-linear template generation and image normalization were
performed using a geodesic shooting procedure.25 The template
was affine registered to the standard brain template from Montreal
Neurological Institute for all subsequent modeling steps. Con-
secutively, normalized CSF tissue segments from all subjects and
time points were modulated by the Jacobian determinants encoding
individual volume changes over time. Morphometric images were
smoothed using Gaussian kernels of 6mm full width at half max-
imum. Subsequent modeling and analysis were performed for
smoothed, normalized CSF segments within specific brain areas.
Statistical analysis
To statistically assess cross-sectional and longitudinal changes
of the CSF/ICV ratio, we used pairwise comparisons for each time
point and linear mixed effects models with a group indicator and
Table 1. Clinical Data of 15 Patients with Subacute











1 19 Complete A C5/C4
2 23 Incomplete B C7/C6
3 70 Incomplete B T10/T10
4 75 Incomplete D T12/T12
5 44 Incomplete D T11/T11
6 42 Complete A C5/C5
7 71 Incomplete B C7/C8
8 20 Complete A C5/C5
9 30 Incomplete B C7/C8
10 52 Incomplete D T9/T9
11 42 Incomplete D C5/C4
12 29 Complete A T11/T11
13 70 Complete A T7/T7
14 52 Incomplete B C6/C6
15 68 Incomplete D C4/C4
2942 SEIF ET AL.
group by time interaction to assess changes over time using STATA
14 (Stata Corp LP, College Station, TX).
To assess group differences in trajectories of local CSF volume
and ventricular enlargements, we followed a conservative two-
stage summary statistics approach commonly used in fMRI and
longitudinal image analysis. In a first stage, we estimated individual
quadratic trajectory models y (t) = b0 + b1 t + b2 t2 and obtained
intercepts (b0), rate of change (b1), quadratic effects (b2), and time
since injury (t) for all subjects in the sample independently. In a
second stage, we used two-sample parametric t tests (for all voxels
within each region of interest [ROI]), comparing the parameters
across clinical groups, while adjusting for age and sex as covariates
of no interest. Group differences of linear (e.g., b1 < 0 indicating
decline) and quadratic (e.g., b2 > 0 indicating deceleration) effects
were assessed using random field theory for correction of multiple
comparisons within each considered ROI.
The associated p values were corrected for multiple comparisons
using family-wise error correction, and cluster significance was
tested (after applying a cluster-forming–threshold of 0.001), using
Gaussian random field theory. Regression models were applied to
determine associations between CSF volume and ventricular ex-
pansion and clinical outcomes over two years of follow-up. The
mean age difference between patients and controls was not found
to be statistically significant ( p= 0.071, Mann–Whitney U test).
However, age was included as a covariate of no interest in all
statistical tests.
For CSF volume, we applied the six-month effect size to cal-
culate estimates of the sample sizes necessary to detect a 100%
treatment effect with 80% statistical power and 5% significant
differences between healthy controls and patient group, by use of
the standard formula based on two-group trials, assuming a baseline
adjusted comparison of mean (analysis of covariance).26 The re-
quired Pearson correlation coefficient between baseline data and
six-month CSF volume was estimated using the available data. The
associations between MRI readouts (i.e., CSF/ICV ratio and ven-
tricle enlargements) and clinical outcomes were investigated using
regression model in SPM 12 and Stata 13.
Results
The local WM and GM changes over two years were estimated
previously from these 33 participants, and the results have been
presented before.7 The mean scan intervals between time of injury
and imaging baseline, two, six, 12, and 24 months were 49.67
(standard error of the mean [SE] 5.91), 103.5 (SE 12.40), 220.36 (SE
18.69), 389.93 (SE 29.60), and 881.14 (SE 43.07) days, respectively.
Global CSF volume
In this study, at baseline, CSF/ICV ratiowas significantly increased
in patients compared with controls (patients=0.21–0.03mL; con-
trols=0.25– 0.05mL, p<0.01). The ratio remained constantly in-
creased (i.e., cross-sectional), but the linear slope of rate of change
was not significantly different between patients and controls over
time (Fig. 1).
Local CSF volume and ventricles enlargement
At baseline, the third ventricle was enlarged (z score = 3.81,
p = 0.011) in patients relative to controls while accounting for age
and sex. Over 24 months, local CSF volume increased linearly (i.e.,
degeneration) over bilateral sensorimotor cortices (left: z score=
4.14 p = 0.002, right: z score= 4.21, p = 0.042) and within the left
supracerebellar space (z score = 4.97, p < 0.001, Fig. 2A,B,C and
Table 2). Testing for potential effects of recovery in terms of de-
celeration and acceleration of the disease process, we found that
the third (z score= 4.60, p= 0.017) and fourth (z score= 3.82,
p= 0.006) ventricle enlargements accelerated (positive quadratic ef-
fect) in patients compared with the controls (Fig. 2A,D,E) over time.
Clinical outcomes correlation
The associations between MRI readouts (i.e., CSF/ICV ratio and
ventricle enlargements) and clinical outcomes showed no signifi-
cant correlations between MRI parameters and clinical outcome
measures.
Sample sizes
Figure 3 demonstrates the sample size requirements for six-
month clinical trials that have 80% statistical power at 5% signif-
icance to detect a 30% treatment effect. For instance, in a six-month
trial that has 80% statistical power (at a two-sided 5% significance
level) to detect 30% changes in CSF volume using VBM model,
25 patients are required per group.
Discussion
This longitudinal study shows that progressive global brain at-
rophy is evident—next to GM and WM atrophy as reported in the
same cohort—early after SCI. At baseline, the CSF/ICV ratio had
increased already and remained so over time without substantial
fluctuations while changes of CSF volume over the sensorimotor
cortex and within the supracerebellar space showed sustained in-
creases. Interestingly, the rate of expansions of the third and fourth
ventricle showed linear and non-linear changes (i.e., acceleration of
the disease process) over time. These dynamic volumetric expan-
sions may be indicative of enduring neurodegenerative processes
within the cortical GM and WM as reported in this cohort before
over two years post-SCI.7 Sample size calculations demonstrated
the sensitivity of acute CSF neuroimaging biomarkers to render
them viable candidates for scoring the effects of treatment, in-
cluding rehabilitation.
Several studies5–7 focused previously on progressive GM and
WM atrophy after SCI but did not address global measures of brain
atrophy such as the CSF/ICV ratio, local CSF volume, and ven-
tricular expansion. Although non-specific to any single disease
process, global measures of brain atrophy have proven sensitive in
tracking disease processes and in picking up treatment-induced
FIG. 1. The cerebrospinal fluid/intracranial volume (CSF/ICV)
ratio across all time points in patients with spinal cord injury and
controls. The CSF/ICV ratio significantly increased at baseline
and remained increased over time in patients compared with
controls accounting for covariates. There was no significant dif-
ference within rates of CSF/ICV ratio at different time points.
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changes in neurodegenerative diseases,8–10 thus rendering them
viable tools in clinical trials.10 Moreover, a previous MRI study on
123 patients with TBI showed that TBI results in the expansion of
CSF spaces, particularly in the temporal horns and third ventricle,
which preceded subsequent reduction in total brain volume.11 A
gradual process of diminishing arborisation of surviving neurons as
a result of disruption of neuronal circuitry might be one possible
explanation for this observation.11
In the current SCI cohort, next to baseline differences of the CSF/
ICV ratio and enlarged third and fourth ventricle, linear increases of
FIG. 2. Longitudinal changes in local cerebrospinal fluid (CSF) volume and ventricle enlargements, shown by longitudinal voxel
based morphometry (VBM) model. (A) Overlay of statistical parametrical maps showing regions of volume changes in local CSF
volume: yellow is baseline intercept, red is linear term, and green is quadratic. (B,C,D,E) Individual longitudinal data points for controls
(blue) and patients (red); colored lines connect the data from each individual. Black solid lines depict the fitted group model describing
average progression in the whole group. Linear (B,C) and quadratic (D,E) group progression models were fitted. All models explicitly
account for effects of covariates of no interest such as age. Color image is available online at www.liebertpub.com/neu












Baseline local CSF volume increase
3.81 0.011 190 -3 -3 -8
Rate of local CSF volume and ventricle size change
CSF (left M1/S1) 4.14 0.002 388 -21 -39 80
CSF (right M1/S1) 4.21 0.042 209 33 -8 71
CSF(left supracerebellar space) 4.97 <0.001 1340 -3 -50 2
Non-linear group differences in ventricle size
Deceleration of third ventricle expansion 4.60 0.017 305 0 -3 6
Deceleration of fourth ventricle expansion 3.82 0.006 380 -5 -41 -29
* Only clusters with significant rates of change between patients and controls are shown.
CSF, cerebrospinal fluid.
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CSF volume were detectable in the supracerebellar space and bi-
laterally over the sensorimotor cortices. The increase of CSF
volume over the sensorimotor cortices might reflect active neu-
rodegeneration within the GM in the output deprived leg re-
presenting area of primary motor cortex.7 The reported focal GM
changes within the sensorimotor cortices (restricted to the leg area)
and thus at the border to the CSF27 might be because of increases in
CSF volume, however, which had been assigned falsely to GM
during segmentation.
Cognitive decline, anxiety, and depression are reported to be
elevated in patients with SCI when compared with the normal
population.28 Crucially, patients with depression showed a higher
CSF volume in other neurodegenerative diseases,29 which may
also be the case in SCI.16 Because these symptoms have been
associated with brain atrophy in other diseases,29 it seems likely
that global brain atrophy in our cohort could be associated with
signs of cognitive impairment. In particular, we have shown
previously that the limbic system in this cohort shows signs of
neurodegeneration.5,6
We did not anticipate that the global measures of the CSF
changes were related to specific functional measures of recovery.
This finding is in line with a previous study in Huntington disease
in which no significant correlations were detected between ven-
tricular volume changes and clinical measures.10 Changes in
imaging outcomes in response to treatment might not always be
accompanied by functional improvements, and clinical function
might sometimes improve in the absence of changes in imaging
measures.10
Thus, although anticipated, our results provide no evidence that
the severity of trauma is related to the rate of change of CSF
measures. This is interesting because it also points to the fact that a
focal CNS injury, such as SCI, might induce a cascade of secondary
neurodegenerative events that progress with a distinct time profile.
The conjoint analysis of CSF volume has the potential to elucidate
whether the chronic inflammatory process within the CSF or the
WM and GM is the main factor driving the observed changes in our
study cohort.
Based on the estimated longitudinal effect sizes of CSF volume,
we recommend CSF volume as an outcome measures to power
clinical trials in SCI. These MRI-based measures may afford the
opportunity to assess site-specific effects of intervention, essential
for the translation of trial efficacy into clinical effectiveness.30
Hypothetical treatment effects, defined by slower longitudinal
structural changes in these imaging measures, could be detectable
over a realistic time scale with significantly lower sample sizes than
required for traditional clinical readouts.31 Thus, these objective
outcome measures hold considerable promise for quantifying the
effects of treatment. In short, quantitative MRI biomarkers of
neurodegeneration therefore represent promising instruments for
the stratification of patient cohorts and the improvement of trial
efficiency.30
Limitations
A limitation of the study is the relatively small number of par-
ticipants that were recruited. In total, however, 156 data points from
patients and controls were included in the analysis and the summary
statistics used maximize the efficiency because all data points were
included. Hypothetical treatment effects defined by slower longi-
tudinal structural changes in these measures would be detectable
over a realistic time scale with practical sample sizes and be
useful in monitoring trauma-induced changes before, during, and
after treatment. Our sample size calculations are made under
several assumptions. We do consider full compliance, no dropout,
any possible effects of treatment response heterogeneity, all of
which might inflate within group variance. The impact of these
confounds, however, is an order of magnitude smaller than the
sample sizes that we present.
Conclusion
We found that CSF/ICV ratio, CSF volume, and ventricular
enlargement rate are sensitive to neurodegenerative changes in SCI
by way of group differences between patients and healthy controls.
The sensitivity to scoring treatment effects speaks to its potential to
serve as a sensitive biomarker in addition to local GM and WM
atrophy measures. The link between inflammatory effects detect-
able within the CSF32,33 and global brain atrophy should be ad-
dressed next.
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